Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €36.54 EUR
Change Today -0.78 / -2.10%
Volume 0.0
As of 9:42 AM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

grifols sa (OZT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/15 - €42.80
52 Week Low
10/16/14 - €28.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GRIFOLS SA (OZT)

Related News

No related news articles were found.

grifols sa (OZT) Related Businessweek News

No Related Businessweek News Found

grifols sa (OZT) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, which include IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, and software for use in diagnostic and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by and in hospitals, such as parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

14,139 Employees
Last Reported Date: 07/30/15
Founded in 1940

grifols sa (OZT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa (OZT) Key Developments

Grifols, S.A. Announces Unaudited Consolidated Earnings Results for the First Half and Second Quarter Ended June 30, 2015

Grifols, S.A. announced unaudited consolidated earnings results for the first half and second quarter ended June 30, 2015. For the period, the company reported net revenue (NR) of EUR 1,900.6 million against EUR 1,610.8 million a year ago. EBITDA was EUR 560.8 million against EUR 508.2 million a year ago. EBIT was EUR 470.7 million against EUR 417.3 million a year ago. Adjusted group profit was EUR 302.8 million against EUR 288.7 million a year ago. Capex was EUR 134.8 million against EUR 125.3 million a year ago. Diluted earnings per share were EUR 0.76 against EUR 0.65 a year ago. Profit before tax was EUR 334,083,000 against EUR 289,573,000 a year ago. Profit was EUR 260,585,000 against EUR 222,971,000 a year ago. Cash flow from operating activities was EUR 257,144,000 against EUR 400,515,000 a year ago. Negative free cash flow was EUR 227,378,000 against EUR 956,049,000 a year ago. The group's net financial debt was EUR 3,818.1 million, including EUR 788.7 million in cash. Profit after income tax from continuing operations was EUR 260,585,000 against EUR 222,971,000 a year ago. Property, plant and equipment and intangible assets were EUR 430,820,000 against EUR 143,178,000 a year ago. Property, plant and equipment were EUR 402,107,000 against EUR 118,601,000 a year ago. Intangible assets were EUR 28,713,000 against EUR 24,577,000 a year ago. For the quarter, the company reported net revenue of EUR 992,181,000 against EUR 812,782,000 a year ago. Operating results was EUR 234,327,000 against EUR 193,470,000 a year ago. Profit before tax was EUR 172,283,000 against EUR 134,203,000 a year ago. Profit after income tax from continuing operations was EUR 132,763,000 against EUR 103,336,000 a year ago. Profit attributable to equity holders of the parent was EUR 133,015,000 against EUR 103,862,000 a year ago. Diluted earnings per share were EUR 0.39 against EUR 0.30 a year ago.

Grifols, S.A. Jointly with Ortho Clinical Diagnostics Enter into Restated and Extended Contract with Abbott for Production of Current Antigens in Addition to Five New Ones in its Manufacturing Facility in Emeryville, California

Grifols, S.A. announced that it has signed, jointly with Ortho Clinical Diagnostics, a restated and extended contract through 2026 with Abbott for the production of current antigens in addition to five new ones in its manufacturing facility in Emeryville, California. The new contract, which extends manufacturing services through 2026, has a total value approximating $700 million. The new facility for the manufacture of recombinant antigens utilized in clinical diagnosis and blood screening, dubbed Project Horizon, is expected to be completed and licensed by the beginning of 2017. Until the new facility is completed and licensed, the antigens will continue to be produced in Grifols’ existing manufacturing facility in Emeryville.

Grifols, S.A. to Report First Half, 2015 Results on Jul 30, 2015

Grifols, S.A. announced that they will report first half, 2015 results on Jul 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OZT:GR €36.54 EUR -0.78

OZT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.120.30 CHF -2.20
Bio-Rad Laboratories Inc $137.21 USD +2.11
Endo International PLC $71.06 USD +1.04
H Lundbeck A/S kr183.30 DKK -4.50
UCB SA €70.57 EUR +0.37
View Industry Companies

Industry Analysis


Industry Average

Valuation OZT Industry Range
Price/Earnings 25.3x
Price/Sales 3.5x
Price/Book 4.2x
Price/Cash Flow 15.8x
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at